Kindeva Drug Delivery, one of the world’s leading contract drug delivery device (CDMO) development and manufacturing organizations, announced that the company has received a grant from the Life Sciences Innovation Manufacturing Fund (LSIMF) of the UK government, unlocking a £33m investment with Kindeva to improve inhaler manufacturing and sustainability. The joint funds enhance Kindeva’s capabilities and ability to design the next generation of environmentally friendly pressurized metered dose inhalers (pMDIs) and continue to provide evolving therapies for respiratory disease worldwide.
“ This joint investment of public and private funds creates many new opportunities for Kindeva people in the UK, as high-level technical and regulatory expertise is required in the development and manufacture of complex inhalers,” said Kindeva Global Chief Commercial Officer David Stevens . “ This investment is a stepping stone for us to scale the business, while working with big pharma around the world to bring the next generation of environmentally friendly inhalers to market, with the common goal of ensuring access to therapies. necessary for patients while preserving the planet.
Also Read: Vial Welcomes Their New Vice President of Central Nervous Systems (CNS), Emma C. Moran
This investment supports the global development and manufacturing of inhalers, using new low-Global Warming Potential (GWP) propellants, while creating and sustaining local jobs at the company’s two sites in the UK, Loughborough and Clitheroe. In addition, this investment from industry and government contributes to the following events:
- Boosting production capacity at Loughborough for the next generation of environmentally friendly aerosols
- Ecological optimizations of Kindeva‘s inhaler component supply chain at the Clitheroe site
- Eco-friendly transitions led by pharmaceutical companies with existing products, reducing PRP emissions and contributing to sustainability goals, as well as the opportunity to bring new eco-friendly inhalers and respiratory therapies to patients.
The UK grant is the sixth investment made by LSIMF, which has supported the UK life sciences manufacturing industry with £340 million through joint government and industry support over the course of the year. past fiscal year.
SOURCE: BusinessWire